179 related articles for article (PubMed ID: 31171817)
1. Targeting translation initiation by synthetic rocaglates for treating MYC-driven lymphomas.
Zhang X; Bi C; Lu T; Zhang W; Yue T; Wang C; Tian T; Zhang X; Huang Y; Lunning M; Hao X; Brown LE; Devine WG; Vose J; Porco JA; Fu K
Leukemia; 2020 Jan; 34(1):138-150. PubMed ID: 31171817
[TBL] [Abstract][Full Text] [Related]
2. Targeting Translation Initiation Bypasses Signaling Crosstalk Mechanisms That Maintain High MYC Levels in Colorectal Cancer.
Wiegering A; Uthe FW; Jamieson T; Ruoss Y; Hüttenrauch M; Küspert M; Pfann C; Nixon C; Herold S; Walz S; Taranets L; Germer CT; Rosenwald A; Sansom OJ; Eilers M
Cancer Discov; 2015 Jul; 5(7):768-781. PubMed ID: 25934076
[TBL] [Abstract][Full Text] [Related]
3. Targeting MYC Translation in Colorectal Cancer.
Castell A; Larsson LG
Cancer Discov; 2015 Jul; 5(7):701-3. PubMed ID: 26152922
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma.
Manier S; Huynh D; Shen YJ; Zhou J; Yusufzai T; Salem KZ; Ebright RY; Shi J; Park J; Glavey SV; Devine WG; Liu CJ; Leleu X; Quesnel B; Roche-Lestienne C; Snyder JK; Brown LE; Gray N; Bradner J; Whitesell L; Porco JA; Ghobrial IM
Sci Transl Med; 2017 May; 9(389):. PubMed ID: 28490664
[TBL] [Abstract][Full Text] [Related]
5. A parasitic fungus employs mutated eIF4A to survive on rocaglate-synthesizing
Chen M; Kumakura N; Saito H; Muller R; Nishimoto M; Mito M; Gan P; Ingolia NT; Shirasu K; Ito T; Shichino Y; Iwasaki S
Elife; 2023 Feb; 12():. PubMed ID: 36852480
[TBL] [Abstract][Full Text] [Related]
6. Oxo-aglaiastatin-Mediated Inhibition of Translation Initiation.
Itoua Maïga R; Cencic R; Chu J; Waller DD; Brown LE; Devine WG; Zhang W; Sebag M; Porco JA; Pelletier J
Sci Rep; 2019 Feb; 9(1):1265. PubMed ID: 30718665
[TBL] [Abstract][Full Text] [Related]
7. Targeting miR-21 with NL101 blocks c-Myc/Mxd1 loop and inhibits the growth of B cell lymphoma.
Li S; He X; Gan Y; Zhang J; Gao F; Lin L; Qiu X; Yu T; Zhang X; Chen P; Tong J; Qian W; Xu Y
Theranostics; 2021; 11(7):3439-3451. PubMed ID: 33537096
[No Abstract] [Full Text] [Related]
8. Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma.
Devlin JR; Hannan KM; Hein N; Cullinane C; Kusnadi E; Ng PY; George AJ; Shortt J; Bywater MJ; Poortinga G; Sanij E; Kang J; Drygin D; O'Brien S; Johnstone RW; McArthur GA; Hannan RD; Pearson RB
Cancer Discov; 2016 Jan; 6(1):59-70. PubMed ID: 26490423
[TBL] [Abstract][Full Text] [Related]
9. AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-Myc B-cell lymphoma in vivo.
Devlin JR; Hannan KM; Ng PY; Bywater MJ; Shortt J; Cullinane C; McArthur GA; Johnstone RW; Hannan RD; Pearson RB
FEBS J; 2013 Nov; 280(21):5307-16. PubMed ID: 23331925
[TBL] [Abstract][Full Text] [Related]
10. Characterization of two new high-grade B-cell lymphoma cell lines with MYC and BCL2 rearrangements that are suitable for in vitro drug sensitivity studies.
Dheur MS; Poirel HA; Ameye G; Tilman G; Saussoy P; Defour JP; Camboni A; Van Den Neste E; Coulie PG; van Baren N
Leuk Lymphoma; 2019 Apr; 60(4):1043-1052. PubMed ID: 30277098
[TBL] [Abstract][Full Text] [Related]
11. Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis.
Nguyen HV; Vandenberg CJ; Ng AP; Robati MR; Anstee NS; Rimes J; Hawkins ED; Cory S
Blood; 2020 Mar; 135(13):1019-1031. PubMed ID: 31978211
[TBL] [Abstract][Full Text] [Related]
12. Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteinexpression" lymphoma with
Uchida A; Isobe Y; Asano J; Uemura Y; Hoshikawa M; Takagi M; Miura I
Haematologica; 2019 Jul; 104(7):1417-1421. PubMed ID: 30523053
[TBL] [Abstract][Full Text] [Related]
13. Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas.
Zappasodi R; Cavanè A; Iorio MV; Tortoreto M; Guarnotta C; Ruggiero G; Piovan C; Magni M; Zaffaroni N; Tagliabue E; Croce CM; Zunino F; Gianni AM; Di Nicola M
Int J Cancer; 2014 Nov; 135(9):2034-45. PubMed ID: 24648290
[TBL] [Abstract][Full Text] [Related]
14. The mitochondrial translation machinery as a therapeutic target in Myc-driven lymphomas.
D'Andrea A; Gritti I; Nicoli P; Giorgio M; Doni M; Conti A; Bianchi V; Casoli L; Sabò A; Mironov A; Beznoussenko GV; Amati B
Oncotarget; 2016 Nov; 7(45):72415-72430. PubMed ID: 27635472
[TBL] [Abstract][Full Text] [Related]
15. Angelica gigas Nakai and Decursin Downregulate Myc Expression to Promote Cell Death in B-cell Lymphoma.
Kim E; Nam J; Chang W; Zulfugarov IS; Okhlopkova ZM; Olennikov D; Chirikova NK; Kim SW
Sci Rep; 2018 Jul; 8(1):10590. PubMed ID: 30002430
[TBL] [Abstract][Full Text] [Related]
16. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.
Petrich AM; Nabhan C; Smith SM
Cancer; 2014 Dec; 120(24):3884-95. PubMed ID: 25060588
[TBL] [Abstract][Full Text] [Related]
17. A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.
Dauch D; Rudalska R; Cossa G; Nault JC; Kang TW; Wuestefeld T; Hohmeyer A; Imbeaud S; Yevsa T; Hoenicke L; Pantsar T; Bozko P; Malek NP; Longerich T; Laufer S; Poso A; Zucman-Rossi J; Eilers M; Zender L
Nat Med; 2016 Jul; 22(7):744-53. PubMed ID: 27213815
[TBL] [Abstract][Full Text] [Related]
18. Management of Patients with MYC-Altered Lymphomas.
Landsburg DJ
Curr Hematol Malig Rep; 2016 Jun; 11(3):208-17. PubMed ID: 26983958
[TBL] [Abstract][Full Text] [Related]
19. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.
Esteve-Arenys A; Valero JG; Chamorro-Jorganes A; Gonzalez D; Rodriguez V; Dlouhy I; Salaverria I; Campo E; Colomer D; Martinez A; Rymkiewicz G; Pérez-Galán P; Lopez-Guillermo A; Roué G
Oncogene; 2018 Apr; 37(14):1830-1844. PubMed ID: 29353886
[TBL] [Abstract][Full Text] [Related]
20. Unexpected favorable outcome in a patient with high grade B-cell lymphoma with abnormalities of MYC, BCL6 and BCL2 loci.
Adams T; Fuchs D; Shadoan PK; Johnstone L; Lau BM; McGhan L; Anwer F; Al-Kateb H
Cancer Genet; 2018 Apr; 222-223():25-31. PubMed ID: 29666005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
